Biblio
Found 48 results
Filters: Author is Brinton, Roberta Diaz [Clear All Filters]
.
2022. Age and sex differences on anti-hyperglycemic medication exposure and risk of newly diagnosed multiple sclerosis in propensity score matched type 2 diabetics.. Heliyon. 8(10):e11196.
.
2022. Androgen-targeting therapeutics mitigate the adverse effect of GnRH agonist on the risk of neurodegenerative disease in men treated for prostate cancer.. Cancer Med. 11(13):2687-2698.
.
2022. Association Between Specific Type 2 Diabetes Therapies and Risk of Alzheimer's Disease and Related Dementias in Propensity-Score Matched Type 2 Diabetic Patients.. Front Aging Neurosci. 14:878304.
.
2022. Contributions of sex and genotype to exploratory behavior differences in an aged humanized mouse model of late-onset Alzheimer's disease.. Learn Mem. 29(9):321-331.
.
2022. Use of oral diabetes medications and the risk of incident dementia in US veterans aged ≥60 years with type 2 diabetes.. BMJ Open Diabetes Res Care. 10(5)
.
2021. ApoE4 Impairs Neuron-Astrocyte Coupling of Fatty Acid Metabolism.. Cell Rep. 34(1):108572.
.
2021. Mitochondria-Targeted Therapeutics for Alzheimer's Disease: The Good, the Bad, the Potential.. Antioxid Redox Signal. 34(8):611-630.
.
2019. Neuroendocrine aging precedes perimenopause and is regulated by DNA methylation.. Neurobiol Aging. 74:213-224.
.
2017. Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease.. Alzheimers Res Ther. 9(1):10.
.
2017. Sex and Race Differences in the Association Between Statin Use and the Incidence of Alzheimer Disease.. JAMA Neurol. 74(2):225-232.
.
2017. Sex differences in Alzheimer risk: Brain imaging of endocrine vs chronologic aging.. Neurology. 89(13):1382-1390.
.
2016. Identifying postmenopausal women at risk for cognitive decline within a healthy cohort using a panel of clinical metabolic indicators: potential for detecting an at-Alzheimer's risk metabolic phenotype.. Neurobiol Aging. 40:155-63.
.
2016. Neuroendocrinology: Oestrogen therapy affects brain structure but not function.. Nat Rev Neurol. 12(10):561-2.
.
2015. Impact of Type 2 Diabetes and Postmenopausal Hormone Therapy on Incidence of Cognitive Impairment in Older Women.. Diabetes Care. 38(12):2316-24.
.
2015. Postmenopausal hormone therapy, type 2 diabetes mellitus, and brain volumes.. Neurology. 85(13):1131-8.
.
2015. Targeting the prodromal stage of Alzheimer's disease: bioenergetic and mitochondrial opportunities.. Neurotherapeutics. 12(1):66-80.
.
2015. White Matter Lipids as a Ketogenic Fuel Supply in Aging Female Brain: Implications for Alzheimer's Disease.. EBioMedicine. 2(12):1888-904.
.
2014. Estrogen: a master regulator of bioenergetic systems in the brain and body.. Front Neuroendocrinol. 35(1):8-30.
.
2014. Frontiers in therapeutic development of allopregnanolone for Alzheimer's disease and other neurological disorders.. Front Cell Neurosci. 8:203.
.
2013. Early decline in glucose transport and metabolism precedes shift to ketogenic system in female aging and Alzheimer's mouse brain: implication for bioenergetic intervention.. PLoS One. 8(11):e79977.
.
2013. Ovariectomy induces a shift in fuel availability and metabolism in the hippocampus of the female transgenic model of familial Alzheimer's.. PLoS One. 8(3):e59825.
.
2013. Potentiation of brain mitochondrial function by S-equol and R/S-equol estrogen receptor β-selective phytoSERM treatments.. Brain Res. 1514:128-41.
.
2013. Window of opportunity for estrogen and progestin intervention in brain aging and Alzheimer's disease.. Brain Res. 1514:1-2.
.
2012. 17β-estradiol and progesterone regulate expression of β-amyloid clearance factors in primary neuron cultures and female rat brain.. Endocrinology. 153(11):5467-79.
.
2012. A dominant negative ERβ splice variant determines the effectiveness of early or late estrogen therapy after ovariectomy in rats.. PLoS One. 7(3):e33493.